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ABSTRACT 
 One therapeutic strategy for cystic fibrosis (CF) seeks to restore anion transport to 
affected epithelia by targeting other apical membrane Cl- channels to bypass dysfunction of the 
cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel.  The properties and 
regulation of the Ca2+-activated Cl- channel TMEM16A argue that long-acting small molecules 
which target directly TMEM16A are required to overcome CFTR loss.  Through genetic studies 
of lung diseases, SLC26A9, a member of the solute carrier 26 family of anion transporters, has 
emerged as a promising target to bypass CFTR dysfunction.  An alternative strategy to 
circumvent CFTR dysfunction is to deliver to CF epithelia artificial anion transporters that 
shuttle Cl- across the apical membrane.  Recently, powerful, non-toxic, biologically-active 
artificial anion transporters have emerged. 
 
  
 3 
 
HIGHLIGHTS 
 Cl- channels distinct from CFTR are found in the apical membrane of CF epithelia. 
 TMEM16A and SLC26A9 are promising targets to bypass CFTR dysfunction in CF. 
 Long-acting drugs that target directly TMEM16A are required to mimic CFTR activity. 
 SLC26A9, a CF disease modifier, supports sustained Cl- secretion by epithelia. 
 Biologically-active artificial anion transporters have been identified. 
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INTRODUCTION 
 The genetic disease cystic fibrosis (CF) is caused by mutations in the epithelial anion 
channel cystic fibrosis transmembrane conductance regulator (CFTR) [1,2], which plays a 
pivotal role in transepithelial ion transport [3].  Because of the large number of disease-causing 
mutations in the CFTR gene (http://www.genet.sickkids.on.ca/app) and their complex effects 
on CFTR expression and function [4], there is significant interest in therapeutic strategies which 
are mutation-independent. 
 
 One mutation-independent therapeutic strategy is to exploit other pathways for anion 
transport in the apical membrane of CF epithelia to rehydrate epithelial surfaces lining ducts 
and tubes (Figure 1).  Most work in this area has focused on the Ca2+-activated Cl- channel and 
has included clinical trials of long-acting P2Y2 receptor agonists that act indirectly by 
increasing the intracellular free Ca2+ concentration [5,6].  However, targeting apical membrane 
Cl- channels is not the only possible approach.  First, inhibition of the epithelial Na+ channel 
(ENaC) prevents dehydration of CF airway epithelia by ENaC-mediated Na+ absorption [7,8].  
Second, activation of basolateral membrane K+ channels enhances the driving force for Cl- exit 
across the apical membrane of CF epithelia through either residual CFTR Cl- channels or other 
apical membrane Cl- channels [9,10].  Third, inhibition of the nongastric H+/K+-ATPase 
(ATP12A) prevents deleterious acidification of airway surface liquid (ASL), which promotes 
bacterial growth [11*].  Finally, artificial anion channels and transporters might be delivered to 
CF epithelia to restore transepithelial Cl- transport [12] (Figure 1).  Here, we examine the utility 
of targeting apical membrane Cl- channels to bypass CFTR dysfunction in CF and discuss recent 
progress in the development of artificial anion transporters. 
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TMEM16A: A TARGET TO STIMULATE ANION TRANSPORT BY AIRWAY 
EPITHELIA 
 TMEM16A (or anoctamin-1 [ANO1]) is the molecular identity of the Ca2+-activated Cl- 
channel [13-15].  It mediates the bidirectional flux of Cl-, HCO3- and other anions across the 
apical membrane of epithelia [5].  When compared to CFTR [2], the structure, function and 
regulation of TMEM16A differ noticeably.  Structural information from a distant paralog, the 
fungus Nectria haematococca [16], argue that TMEM16A is a homodimer with each subunit 
containing at least ten membrane-spanning helices and a Ca2+-binding site.  Intriguingly, the 
TMEM16A pore might only in part be delimited by transmembrane helices, the remainder being 
formed in some way by lipids of the plasma membrane [17*].  This unconventional pore 
structure arises from the lipid scramblase function of distant paralogs [16].  A cleft on each side 
of the homodimer forms a pathway through which the heads of phospholipids can translocate 
from one side of the membrane to the other.  Although scramblase activity has been conserved 
in some family members, such as TMEM16F [18], in TMEM16A and TMEM16B, the pathway 
for lipid head translocation has evolved into a pore for anions. 
 
 TMEM16A is expressed in the airway epithelium, although its localisation appears 
different to that of CFTR.  In the surface epithelium, CFTR is predominantly expressed in 
ciliated cells, whereas TMEM16A is more abundant in mucus-secreting goblet cells [19,20].  
Like CFTR, TMEM16A is also present in submucosal glands of the bronchi [21].  Interestingly, 
TMEM16A expression is increased under pro-inflammatory conditions (e.g. treatment with 
cytokines or bacterial components), which lead to mucus hypersecretion [19,21,22]. 
 
 Physiologically, TMEM16A is activated by stimuli that mobilise intracellular Ca2+, 
such as purinergic agonists.  In the surface epithelium, this mechanism might link release of 
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intracellular ATP [23], caused by mechanical stress (e.g. cough) or other stimuli, to activation 
of TMEM16A-dependent anion secretion.  As revealed by short-circuit current recordings (one 
measure of transepithelial ion transport), Ca2+-dependent secretion is usually characterised by 
a large transient, attained a few seconds after stimulation, which declines to near resting levels 
within 15-20 minutes [5] (Figure 2).  This behaviour suggests that TMEM16A is involved in 
rapid adaptation to conditions where increased anion secretion is required.  Given its 
localisation in goblet cells, TMEM16A might play an important role mediating bicarbonate 
secretion to support mucus release.  By contrast, CFTR function has a more “tonic” role.  Its 
activity is maintained for prolonged periods [3] (Figure 2), suggesting that CFTR contributes 
to basal anion secretion. 
 
 Nevertheless, TMEM16A might represent an alternative therapeutic target to 
circumvent CFTR dysfunction in the airway epithelia of CF patients.  Pharmacological 
stimulation of TMEM16A function could help to normalise the properties of airway surface 
liquid and mucus by increasing chloride and bicarbonate secretion.  For example, TMEM16A 
stimulation might be used as an adjuvant therapy, in combination with CFTR modulators that 
rescue the apical membrane expression and function of CF mutants.  It might be especially 
valuable to individuals carrying CF mutations unresponsive to CFTR modulator therapy. 
 
 An ideal drug stimulating TMEM16A should act directly upon TMEM16A, not work 
through elevation of intracellular Ca2+ [24].  It should also produce long-lasting activation of 
TMEM16A to mimic the normal behaviour of CFTR.  Finally, this drug should be delivered by 
nebulization to avoid systemic administration, which might elicit unnecessary and potentially 
harmful TMEM16A activation in other organs and tissues, but it also should avoid activation 
of TMEM16A in bronchial smooth muscle to prevent bronchial constriction [5].  Of note, 
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Danahay et al. (Poster 91, 14th European Cystic Fibrosis Society Basic Science Conference, 
Albufeira, Portugal, March 2017) reported the identification of chemical structures that 
potentiate TMEM16A independent of elevation of intracellular Ca2+.  It is also feasible that 
TMEM16A activators and potentiators might be identified among the chemical structures of 
TMEM16A inhibitors identified by high throughput screening [5,24].  Lessons from the 
development of CFTR modulators will no doubt accelerate work to transform small molecule 
TMEM16A modulators into therapeutics for CF lung disease. 
 
SLC26A9: AN ALTERNATIVE TARGET TO BYPASS CFTR DYSFUNCTION IN CF 
 One member of the solute carrier 26 (SLC26) family of anion transporters, SLC26A9 
has recently been identified as a promising target to bypass CFTR dysfunction in CF epithelia 
[25,26].  While most SLC26 proteins function as anion transporters, SLC26A9 is a Cl--selective 
channel with limited HCO3- conductance [25,27].  Like CFTR, the SLC26A9 Cl- channel has a 
linear current-voltage (I-V) relationship with a low single-channel conductance [25,28,29].  
However, in marked contrast to CFTR and TMEM16A, which are tightly regulated by cAMP-
dependent phosphorylation and the intracellular free Ca2+ concentration, respectively [2,5], 
SLC26A9 is constitutively active, supporting sustained Cl- secretion once inserted into the 
apical membrane of airway epithelia [25,26,29,30] (Figure 2).  These data argue that SLC26A9 
is an important target for mutation-independent therapy in CF. 
 
 The predicted topology of SLC26A9 contains a PDZ-binding motif at its C-terminus 
through which SLC26A9 can interact with CFTR, if both proteins are expressed in the same 
cell [31-33*].  Consistent with this idea, co-expression of SLC26A9 with wild-type CFTR 
increased the function of both Cl- channels, whereas co-expression of SLC26A9 with the CF 
mutant F508del-CFTR, which fails to reach the plasma membrane, reduced SLC26A9 function 
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[25,33*,34].  These reciprocal interactions of CFTR and SLC26A9 are likely relevant for the 
pathophysiology and pharmacotherapy of CF lung disease.  First, inhibition of constitutive 
SLC26A9 activity in airway epithelia by F508del-CFTR might abrogate an important fail-safe 
mechanism for Cl- secretion, thus aggravating the dehydration of epithelial surfaces in CF 
patients carrying the F508del-CFTR mutation.  Conversely, SLC26A9 might augment the 
residual function and pharmacological rescue of CF mutants present at the apical membrane 
(e.g. the gating mutation G551D-CFTR).  Consistent with these ideas, Strug et al. [35*] found 
an association between a single nucleotide polymorphism in the SLC26A9 gene and the 
magnitude of treatment response in CF patients with gating mutations treated with the CFTR 
potentiator ivacaftor.  The authors also found improved transepithelial Cl- transport in F508del 
homozygous primary bronchial epithelial cultures treated with the CFTR corrector lumacaftor.  
These and other data [36] argue that SLC26A9 acts as a modifier of CF lung disease severity 
and the response to CFTR modulator therapy. 
 
 Further evidence supporting SLC26A9 as a promising therapeutic target for muco-
obstructive lung diseases was obtained using SLC26A9-deficient mice challenged with 
intrapulmonary installation of the Th2 cytokine IL-13 to induce goblet cell metaplasia and 
mucus hypersecretion [30].  Like TMEM16A [13], SLC26A9 function is induced by IL-13 
treatment [30].  In wild-type mice treated with IL-13, SLC26A9-mediated Cl- secretion 
prevented airway mucus obstruction despite substantial mucus hypersecretion, whereas in 
SLC26A9-deficient mice treated with IL-13, which lacked this Cl- secretory capacity, severe 
airway mucus plugging developed [30].  Interestingly, studies of CFTR-deficient mice revealed 
that concomitant absence of SLC26A9 causes a substantial increase in gastrointestinal tract-
related mortality, indicating that SLC26A9 is a genetic modifier of meconium ileus-like 
intestinal obstruction in CF mice [37].  Consistent with this idea, SLC26A9 polymorphisms 
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have also been associated with the risk to develop meconium ileus and early exocrine pancreatic 
disease in CF patients [38,39]. 
 
 In summary, SLC26A9 has emerged as a promising therapeutic target to bypass CFTR 
dysfunction in the respiratory airways, gastrointestinal tract and pancreas of CF patients.  
However, current knowledge of the SLC26A9 Cl- channel is limited.  Considerable research is 
therefore required before SLC26A9 can be tested as a therapeutic target in patients with CF and 
potentially other muco-obstructive lung diseases.  The crystal structure of an SLC26 homolog 
from the bacterium Deinocoocus geothermalis, a proton-driven fumarate transporter [40] 
should accelerate progress towards this goal. 
 
BIOLOGICALLY-ACTIVE ARTIFICIAL ANION TRANSPORTERS 
 An alternative approach to CFTR bypass therapy is to create artificial pathways for 
anion transport that can be inserted into the apical membrane of CF epithelia to mediate 
transepithelial Cl- transport.  Transmembrane Cl- transport might be achieved using static 
pathways for anion movement (synthetic anion channels) or small molecules, which shuttle 
anions across cells membranes (artificial anion transporters or anionophores) (Figure 1).  In an 
early proof of principle study, Wallace et al. [41] demonstrated that a synthetic peptide derived 
from the glycine receptor induced sustained transepithelial Cl- secretion across cultured renal 
epithelia.  Subsequently, self-assembled non-peptide synthetic anion channels have been 
developed and their biological activity assessed [12,42].  Of note, Jiang et al. [43] demonstrated 
that a squalamine analogue, functioning as a synthetic Cl- channel, partially corrected loss of 
CFTR function in CF airway cells, epithelia and the nasal epithelium of a CF mouse model.  
Subsequently, Shen et al. [44] showed that a synthetic Cl- channel based on a C2-symmetric 
isophthalamide scaffold conferred a Cl- conductance on CF airway epithelial cells, while a 
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modified C2-symmetric isophthalamide scaffold has been identified, which transports Cl- and 
HCO3- across synthetic lipid vesicles and airway epithelia and confers Cl- transport on CF 
airway epithelia [45]. 
 
 The successful development of biologically-active anionophores depends greatly on 
their chemical structure.  This chemical structure should bind anions at the interface between 
the aqueous extracellular environment and the plasma membrane, translocate them across the 
lipid bilayer before release on the intracellular side (Figure 1).  Anionophores therefore require 
solubility within the lipid bilayer, while forming a binding site for anions shielded from the 
lipid bilayer.  These characteristics are well illustrated by cholapods, steroid-based scaffolds 
derived from cholic acid [46-48].  The lipophilic nature of cholic acid promotes solubility in 
lipid membranes, while its rigid structure has well-spaced side groups that can be modified to 
form a high-affinity Cl- binding site (for review, see [48]) (Figure 3).  When tested in synthetic 
lipid vesicles, cholapods proved to be powerful anion transporters, some exhibiting anion 
transport at cholapod to lipid ratios as low as 1:250,000 (i.e. one or two anionophores per lipid 
vesicle) [47,48].  The observation that the central part of the cholapod structure contained most 
of its anion transport activity [48] motivated the development of a second family of 
anionophores, termed decalins [49] (Figure 3).  Of note, decalins have improved drug-like 
properties, including smaller molecular weight and reduced lipophilicity, making them easier 
to partition from aqueous to lipid environments.  Moreover, some decalins achieve impressive 
transport rates in synthetic lipid vesicles, approaching that of CFTR in natural membranes [50]. 
 
 Using cells engineered to express the halide-sensitive fluorophore YFP-H148Q/I152L 
[51], Li et al. [52*] tested the biological activity of 15 anionophores representative of different 
chemical scaffolds, including cholapods [46,47], decalins [49,50] and cyclohexanes [53].  One 
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decalin, a bis-ureiododecalin demonstrated especially promising activity, including (i) delivery 
to cell membranes from the aqueous solution, (ii) potency at low micromolar concentrations, 
(iii) sustained activity, transporting anions for up to 2 hours and (iv) lack of cytotoxic effects 
when tested on three different epithelial cell lines [52*].  These data argue that anionophores 
are worthy of further investigation as a CFTR bypass therapy for CF.  However, important 
challenges remain to be addressed, including optimisation of chemical structure, regulation and 
delivery to airway epithelia in vivo.  Encouragingly, recent data argue that anionophores with 
encapsulated Cl- binding sites will likely achieve transmembrane Cl- transport with high Cl- 
selectivity [54*].  Given the importance of HCO3- for epithelial physiology (e.g. [11*,55]), 
future studies should also seek to develop anionophores capable of transmembrane HCO3- 
transport. 
 
CONCLUSIONS 
 Mutation-independent therapies that circumvent CFTR dysfunction have a key role to 
play in the armamentarium of innovative new therapies that tackle the root cause of CF.  These 
therapies are likely to be particularly useful for individuals carrying mutations that are not 
amenable to treatment with small molecule CFTR modulators.  The molecular identification of 
TMEM16A has accelerated the search for long-acting small molecule activators and 
potentiators of the epithelial Ca2+-activated Cl- channel to achieve sustained transepithelial Cl- 
secretion.  SLC26A9 is an attractive target to circumvent CFTR dysfunction in CF, but much 
remains to be learnt about this epithelial Cl- channel before therapeutically-active small 
molecule SLC26A9 activators and potentiators are developed.  Similarly, work to develop 
therapeutically-active anionophores is at an early stage, but the identification of powerful, non-
toxic biologically-active anionophores augurs well for the future.  Evaluation of CFTR bypass 
strategies using animal models (ferrets and pigs) resembling CF disease in humans and 
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organotypic cell cultures will be important for their development as therapeutic tools for CF 
lung disease. 
 
  
 13 
 
ACKNOWLEDGEMENTS 
 We thank our laboratory colleagues and collaborators for stimulating discussions.  Work 
in the authors’ laboratories discussed in this manuscript was supported by the Engineering and 
Physical Sciences Research Council [grant nos. EP/F03623X/1 and EP/J00961X/1] (HL and 
DNS), German Ministry for Education and Research [grant no. 82DZL004A1] (JJS and MAM) 
and Telethon Foundation [grant no. TMLGCBX16TT] (LJVG).  This review uses published 
research only.  No new data were collected or generated in its preparation. 
 
CONFLICT OF INTEREST STATEMENT 
 The authors have no conflict of interest to declare. 
 
  
 14 
 
REFERENCES 
 
1.  Riordan JR, Rommens JM, Kerem B-S, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, 
Lok S, Plavsic N, Chou J-L et al.: Identification of the cystic fibrosis gene: cloning and 
characterization of complementary DNA. Science 1989, 245:1066-1073. 
 
2.  Gadsby DC, Vergani P, Csanády L: The ABC protein turned chloride channel whose 
failure causes cystic fibrosis. Nature 2006, 440:477-483. 
 
3.  Frizzell RA, Hanrahan JW: Physiology of epithelial chloride and fluid secretion. Cold 
Spring Harb Perspect Med 2012, 2:a009563. 
 
4.  Veit G, Avramescu RG, Chiang AN, Houck SA, Cai Z, Peters KW, Hong JS, Pollard HB, 
Guggino WB, Balch WE et al.: From CFTR biology towards combinatorial 
pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell 
2016, 27:424-433. 
 
5.  Pedemonte N, Galietta LJV: Structure and function of TMEM16 proteins 
(anoctamins). Physiol Rev 2014, 94:419-459. 
 
6.  Moss RB: Pitfalls of drug development: lessons learned from trials of denufosol in 
cystic fibrosis. J Pediatr 2013, 162:676-680. 
 
7.  Coote KJ, Paisley D, Czarnecki S, Tweed M, Watson H, Young A, Sugar R, Vyas M, 
Smith NJ, Baettig U et al.: NVP-QBE170: an inhaled blocker of the epithelial sodium 
 15 
 
channel with a reduced potential to induce hyperkalaemia. Br J Pharmacol 2015, 
172:2814-2826. 
 
8.  Scott DW, Walker MP, Sesma J, Wu B, Stuhlmiller TJ, Sabater JR, Abraham WM, 
Crowder TM, Christensen DJ, Tarran R: SPX-101 is a novel ENaC-targeted 
therapeutic for cystic fibrosis that restores mucus transport. Am J Respir Crit Care 
Med 2017, doi: 10.1164/rccm.201612-2445OC. 
 
9.  Devor DC, Bridges RJ, Pilewski JM: Pharmacological modulation of ion transport 
across wild-type and F508 CFTR-expressing human bronchial epithelia. Am J 
Physiol Cell Physiol 2000, 279:C461-C479. 
 
10.  Mall M, Wissner A, Schreiber R, Kuehr J, Seydewitz HH, Brandis M, Greger R, 
Kunzelmann K: Role of KVLQT1 in cyclic adenosine monophosphate-mediated Cl- 
secretion in human airway epithelia. Am J Respir Cell Mol Biol 2000, 23:283-289. 
 
11.  Shah VS, Meyerholz DK, Tang XX, Reznikov L, Abou Alaiwa M, Ernst SE, Karp PH, 
Wohlford-Lenane CL, Heilmann KP, Leidinger MR et al.: Airway acidification initiates 
host defense abnormalities in cystic fibrosis mice. Science 2016, 351:503-507. 
(*)  The authors demonstrate that the nongastric H+/K+-ATPase (ATP12A) is expressed in 
human and pig (but not mouse) airway epithelia, where it mediates H+ secretion.  
Inhibition of ATP12A restores bacterial killing to human and pig airway epithelia, 
whereas expression of ATP12A in mouse airway epithelia impairs the killing of bacteria.  
The data highlight the therapeutic potential of ATP12A inhibitors in CF. 
 
 16 
 
12.  Davis AP, Sheppard DN, Smith BD: Development of synthetic membrane transporters 
for anions. Chem Soc Rev 2007, 36:348-357. 
 
13.  Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, Pfeffer U, Ravazzolo 
R, Zegarra-Moran O, Galietta LJV: TMEM16A, a membrane protein associated with 
calcium-dependent chloride channel activity. Science 2008, 322:590-594. 
 
14.  Schroeder BC, Cheng T, Jan YN, Jan LY: Expression cloning of TMEM16A as a 
calcium-activated chloride channel subunit. Cell 2008, 134:1019-1029. 
 
15.  Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim W-S, Park SP, Lee J, Lee B, Kim B-
M et al.: TMEM16A confers receptor-activated calcium-dependent chloride 
conductance. Nature 2008, 455:1210-1215. 
 
16.  Brunner JD, Lim NK, Schenck S, Duerst A, Dutzler R: X-ray structure of a calcium-
activated TMEM16 lipid scramblase. Nature 2014, 516:207-212. 
 
17.  Whitlock JM, Hartzell HC: A pore idea: the ion conduction pathway of 
TMEM16/ANO proteins is composed partly of lipid. Pflügers Archiv 2016, 468:455-
473. 
(*)  The authors integrate structural and functional data to propose the innovative idea that the 
pathway for transmembrane Cl- flow in TMEM16A is formed in part by the lipid bilayer. 
 
18.  Suzuki J, Umeda M, Sims PJ, Nagata S: Calcium-dependent phospholipid scrambling 
by TMEM16F. Nature 2010, 468:834-838. 
 17 
 
 
19.  Huang F, Zhang H, Wu M, Yang H, Kudo M, Peters CJ, Woodruff PG, Solberg OD, 
Donne ML, Huang X et al.: Calcium-activated chloride channel TMEM16A 
modulates mucin secretion and airway smooth muscle contraction. Proc Natl Acad 
Sci U S A 2012, 109:16354-16359. 
 
20.  Scudieri P, Caci E, Bruno S, Ferrera L, Schiavon M, Sondo E, Tomati V, Gianotti A, 
Zegarra-Moran O, Pedemonte N et al.: Association of TMEM16A chloride channel 
overexpression with airway goblet cell metaplasia. J Physiol 2012, 590:6141-6155. 
 
21.  Caci E, Scudieri P, Di Carlo E, Morelli P, Bruno S, De Fino I, Bragonzi A, Gianotti A, 
Sondo E, Ferrera L et al.: Upregulation of TMEM16A protein in bronchial epithelial 
cells by bacterial pyocyanin. PLoS ONE 2015, 10:e0131775. 
 
22.  Gorrieri G, Scudieri P, Caci E, Schiavon M, Tomati V, Sirci F, Napolitano F, Carrella D, 
Gianotti A, Musante I et al.: Goblet cell hyperplasia requires high bicarbonate 
transport to support mucin release. Sci Rep 2016, 6:36016. 
 
23.  Button B, Okada SF, Frederick CB, Thelin WR, Boucher RC: Mechanosensitive ATP 
release maintains proper mucus hydration of airways. Sci Signal 2013, 6:ra46. 
 
24.  Namkung W, Yao Z, Finkbeiner WE, Verkman AS: Small-molecule activators of 
TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride 
secretion and intestinal contraction. FASEB J 2011, 25:4048-4062. 
 
 18 
 
25.  Bertrand CA, Zhang R, Pilewski JM, Frizzell RA: SLC26A9 is a constitutively active, 
CFTR-regulated anion conductance in human bronchial epithelia. J Gen Physiol 
2009, 133:421-438. 
 
26.  Mall MA, Galietta LJV: Targeting ion channels in cystic fibrosis. J Cyst Fibros 2015, 
14:561-570. 
 
27.  Loriol C, Dulong S, Avella M, Gabillat N, Boulukos K, Borgese F, Ehrenfeld J: 
Characterization of SLC26A9, facilitation of Cl- transport by bicarbonate. Cell 
Physiol Biochem 2008, 22:15-30. 
 
28.  Chang M-H, Plata C, Zandi-Nejad K, Sindić A, Sussman CR, Mercado A, Broumand V, 
Raghuram V, Mount DB, Romero MF: Slc26a9–anion exchanger, channel and Na+ 
transporter. J Membr Biol 2009, 228:125-140. 
 
29.  Salomon JJ, Spahn S, Wang X, Füllekrug J, Bertrand CA, Mall MA: Generation and 
functional characterization of epithelial cells with stable expression of SLC26A9 Cl- 
channels. Am J Physiol Lung Cell Mol Physiol 2016, 310:L593-L602. 
 
30.  Anagnostopoulou P, Riederer B, Duerr J, Michel S, Binia A, Agrawal R, Liu X, Kalitzki 
K, Xiao F, Chen M et al.: SLC26A9-mediated chloride secretion prevents mucus 
obstruction in airway inflammation. J Clin Invest 2012, 122:3629-3634. 
 
31.  Chang M-H, Plata C, Sindic A, Ranatunga WK, Chen A-P, Zandi-Nejad K, Chan KW, 
Thompson J, Mount DB, Romero MF: Slc26a9 is inhibited by the R-region of the cystic 
 19 
 
fibrosis transmembrane conductance regulator via the STAS domain. J Biol Chem 
2009, 284:28306-28318. 
 
32.  El Khouri E, Touré A: Functional interaction of the cystic fibrosis transmembrane 
conductance regulator with members of the SLC26 family of anion transporters 
(SLC26A8 and SLC26A9): physiological and pathophysiological relevance. Int J 
Biochem Cell Biol 2014, 52:58-67. 
 
33.  Bertrand CA, Mitra S, Mishra SK, Wang X, Zhao Y, Pilewski JM, Madden DR, Frizzell 
RA: The CFTR trafficking mutation F508del inhibits the constitutive activity of 
SLC26A9. Am J Physiol Lung Cell Mol Physiol 2017, 312:L912-L925. 
(*)  The most common CF mutation F508del-CFTR disrupts SLC26A9-CFTR interactions 
mediated by PDZ domains, leading to decreased plasma membrane expression of 
SLC26A9.  The CFTR corrector lumacaftor rescues SLC26A9 by trafficking F508del-
CFTR to the plasma membrane. 
 
34.  Avella M, Loriol C, Boulukos K, Borgese F, Ehrenfeld J: SLC26A9 stimulates CFTR 
expression and function in human bronchial cell lines. J Cell Physiol 2010, 226:212-
223. 
 
35.  Strug LJ, Gonska T, He G, Keenan K, Ip W, Boëlle P-Y, Lin F, Panjwani N, Gong J, Li 
W et al.: Cystic fibrosis gene modifier SLC26A9 modulates airway response to 
CFTR-directed therapeutics. Hum Mol Genet 2016, 25:4590-4600. 
 20 
 
(*)  In CF patients with gating mutations, there is variability in the improvement in lung 
function achieved using the CFTR potentiator ivacaftor.  The authors demonstrate that the 
CF modifier gene SLC26A9 contributes in part to this variability. 
 
36.  Bakouh N, Bienvenu T, Thomas A, Ehrenfeld J, Liote H, Roussel D, Duquesnoy P, 
Farman N, Viel M, Cherif-Zahar B et al.: Characterization of SLC26A9 in patients 
with CF-like lung disease. Hum Mutat 2013, 34:1404-1414. 
 
37.  Liu X, Li T, Riederer B, Lenzen H, Ludolph L, Yeruva S, Tuo B, Soleimani M, Seidler 
U: Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO3- 
transport and reduces survival in CFTR-deficient mice. Pflügers Archiv 2015, 
467:1261-1275. 
 
38.  Sun L, Rommens JM, Corvol H, Li W, Li X, Chiang TA, Lin F, Dorfman R, Busson P-F, 
Parekh RV et al.: Multiple apical plasma membrane constituents are associated with 
susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet 2012, 
44:562-569. 
 
39.  Miller MR, Soave D, Li W, Gong J, Pace RG, Boëlle P-Y, Cutting GR, Drumm ML, 
Knowles MR, Sun L et al.: Variants in solute carrier SLC26A9 modify prenatal 
exocrine pancreatic damage in cystic fibrosis. J Pediatr 2015, 166:1152-1157. 
 
40.  Geertsma ER, Chang Y-N, Shaik FR, Neldner Y, Pardon E, Steyaert J, Dutzler R: 
Structure of a prokaryotic fumarate transporter reveals the architecture of the 
SLC26 family. Nat Struct Mol Biol 2015, 22:803-808. 
 21 
 
 
41.  Wallace DP, Tomich JM, Iwamoto T, Henderson K, Grantham JJ, Sullivan LP: A 
synthetic peptide derived from glycine-gated Cl- channel induces transepithelial Cl- 
and fluid secretion. Am J Physiol Cell Physiol 1997, 272:C1672-C1679. 
 
42.  Sidorov V, Kotch FW, Abdrakhmanova G, Mizani R, Fettinger JC, Davis JT: Ion channel 
formation from a calix[4]arene amide that binds HCl. J Am Chem Soc 2002, 124:2267-
2278. 
 
43.  Jiang C, Lee ER, Lane MB, Xiao Y-F, Harris DJ, Cheng SH: Partial correction of 
defective Cl- secretion in cystic fibrosis epithelial cells by an analog of squalamine. 
Am J Physiol Lung Cell Mol Physiol 2001, 281:L1164-L1172. 
 
44.  Shen B, Li X, Wang F, Yao X, Yang D. A synthetic chloride channel restores chloride 
conductance in human cystic fibrosis epithelial cells. PLoS ONE 2012, 7:e34694. 
 
45.Liu PY, Li ST, Shen FF, Ko WH, Yao XQ, Yang D. A small synthetic molecule functions 
as a chloride-bicarbonate dual-transporter and induces chloride secretion in cells. 
Chem Commun 2016; 52:7380-7383. 
 
46.  Koulov AV, Lambert TN, Shukla R, Jain M, Boon JM, Smith BD, Li H, Sheppard DN, 
Joos J-B, Clare JP, et al.: Chloride transport across vesicle and cell membranes by 
steriod-based receptors. Angew Chem Int Ed Engl 2003, 42:4931-4933. 
 
 22 
 
47.  McNally BA, Koulov AV, Lambert TN, Smith BD, Joos J-B, Sisson AL, Clare JP, 
Sgarlata V, Judd LW, Magro G, et al.: Structure-activity relationships in cholapod 
anion carriers: enhanced transmembrane chloride transport through substituent 
tuning. Chemistry 2008, 14:9599-9606. 
 
48.  Valkenier H, Davis AP: Making a match for valinomycin: steroidal scaffolds in the 
design of electroneutral, electrogenic anion carriers. Acc Chem Res 2013, 46:2898-
2909. 
 
49.  Hussain S, Brotherhood PR, Judd LW, Davis AP: Diaxial diureido decalins as compact, 
efficient, and tunable anion transporters. J Am Chem Soc 2011, 133:1614-1617. 
 
50.  Valkenier H, Judd LW, Li H, Hussain S, Sheppard DN, Davis AP: Preorganized bis-
thioureas as powerful anion carriers: chloride transport by single molecules in large 
unilamellar vesicles. J Am Chem Soc 2014, 136:12507-12512. 
 
51.  Galietta LJV, Haggie PM, Verkman AS: Green fluorescent protein-based halide 
indicators with improved chloride and iodide affinities. FEBS Lett 2001, 499:220-224. 
 
52.  Li H, Valkenier H, Judd LW, Brotherhood PR, Hussain S, Cooper JA, Jurček O, Sparkes 
HA, Sheppard DN, Davis AP: Efficient, non-toxic anion transport by synthetic 
carriers in cells and epithelia. Nat Chem 2016, 8:24-32. 
(*) Using halide-sensitive YFP to monitor anion transport, the authors identify an artificial 
anion transporter with promising biological activity, including delivery to cell 
membranes, potency, persistence and lack of cytotoxic effects. 
 23 
 
 
53.  Cooper JA, Street STG, Davis AP: A flexible solution to anion transport: powerful 
anionophores based on a cyclohexane scaffold. Angew Chem Int Ed Engl 2014, 
53:5609-5613. 
 
54.  Wu X, Judd LW, Howe ENW, Withecombe AM, Soto-Cerrato V, Li H, Busschaert N, 
Valkenier H, Pérez-Tomás R, Sheppard DN et al.: Nonprotonophoric electrogenic Cl- 
transport mediated by valinomycin-like carriers. Chem 2016, 1:127-146. 
(*) The authors identify new anionophores, which promote electrogenic Cl- transport 
mimicking electrogenic K+ transport by valinomycin.  The data argue that encapsulation 
of the Cl- binding site is important for the design of anionophores with optimal Cl- 
transport properties. 
55. Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires 
cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin 
Invest 2009, 119:2613-2622. 
 
  
 24 
 
FIGURE LEGENDS 
Figure 1: Pharmacological rescue of epithelial Cl- transport in CF by targeting alternative 
Cl- channels or using artificial anion channels and transporters  The schematic shows a 
thin layer of airway surface liquid (ASL) covering the airway surface epithelium and a 
submucosal gland.  The activity of CFTR and the epithelial Na+ channel (ENaC) in the apical 
membrane controls the quantity and composition of ASL.  Submucosal glands deliver mucus 
and antimicrobial factors to the ASL.  The insets show the cellular mechanism of CFTR-
dependent Cl- secretion and mechanisms to bypass CFTR dysfunction in CF: activation of 
TMEM16A and SLC26A9, Cl- channels endogenously expressed in the apical membrane of 
goblet and ciliated cells of the airway epithelia and artificial anion channels and transporters 
that might be delivered to airway epithelia by nebulisation.  Abbreviations: CFTR, cystic 
fibrosis transmembrane conductance regulator; ENaC, epithelial Na+ channel; SLC26A9, solute 
carrier 26 member A9; TMEM16A, transmembrane member 16A.  For further information, see 
the text. 
 
Figure 2: Time course of Cl- current mediated by CFTR, TMEM16A, SLC26A9 and a 
bis-ureiododecalin anionophore  (A – E)  Time courses of transepithelial Cl- current recorded 
with the Ussing chamber technique.  The recordings are from human bronchial epithelia 
endogenously expressing CFTR and TMEM16A (A, B); Fischer rat thyroid (FRT) epithelia 
expressing recombinant SLC26A9 and control transfected epithelia (C); Madin Darby canine 
(MDCK) epithelia endogenously expressing canine CFTR (D) and FRT epithelia treated with 
a bis-ureiododecalin anionophore (2 M) or the vehicle POPC (20 M) (E).  All recordings 
were made in the presence of a Cl- concentration gradient with [Cl-]basolateral > [Cl-]apical.  In A-
C, the epithelium was intact, whereas in D and E, the basolateral membrane was permeabilised 
with nystatin (0.36 mg ml-1; Sigma-Aldrich).  Arrows indicate the addition of the cAMP 
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agonists CPT-cAMP (100 M) (A), forskolin (Fsk; 1 M) with 3-isobutyl-1-methylxanthine 
(IBMX; 100 M) (C) and forskolin (10 M) (D); the P2Y2 agonist UTP (100 M) (B) and the 
start of the recording (C).  Recordings were ended without using inhibitors to return current to 
baseline except A and E, where this was achieved using CFTRinh-172 (I172; 10 M) and by 
removing the [Cl-] gradient (E); dashed lines indicate the basal current level.  For further 
information, see the text.  Reproduced, with permission, from Salomon et al. [29] and Li et al. 
[50*]. 
 
Figure 3: Cholapod and decalin anionophores  The chemical structures of some biologically-
active cholapods (where R = CF3 and NO2; X = OCH3) and decalins (where R = CF3 and NO2; 
X = OC2H5) are shown together with the crystal structure of the bis-ureiododecalin with 
Me4N+Cl-.  In the crystal structure, the dashed lines denote hydrogen bonds that bind the Cl- 
ion; the Me4N+ cation is shown in pink.  Modified, with permission, from Li et al. [50*]. 
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